FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Lilly Q3 Results - Q3 Top Pharma Company Earnings Reports

Tools

View Lilly's Q3 Earnings Report

FiercePharma says: Lilly posted $941.8 million in third-quarter net income, way up from last year's $465.6 million loss on charges. More impressively, however, the company managed to boost sales by 6.8 percent during a quarter when its rivals had a tough time on the revenue side.. Read more of our coverage here...

Highlights:

  • Higher volume drives revenue growth
  • Stronger dollar results in improved gross margin
  • Earnings per share increase to $.86 (reported) or $1.20 (pro forma non-GAAP)
  • Full-year 2009 EPS guidance range revised to $3.90 - $4.00 (reported) or $4.30 - $4.40 (pro forma non-GAAP)

Check out Lilly's current earnings estimates from CNN Money

Lilly's Website: http://www.lilly.com/

Related Articles:
Lilly juggles jobs for emerging-markets growth
Cost-conscious Medco pits Plavix against Effient
Lilly's promo deal with CVS draws fire
Lilly offloads 700-worker Indiana plant


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Eli Lilly  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.